BEIGENE (06160) Schedules 25 Mar 2026 Audit Committee Meeting to Confirm FY2025 Results and HKEX Disclosure

Bulletin Express03-11

BeOne Medicines Ltd. (trading as BEIGENE; stock code 06160) has announced that its Board Audit Committee will convene on 25 March 2026 (Hong Kong time) to review and approve the consolidated annual results for the financial year ended 31 December 2025.

The company previously disclosed the same FY2025 financials in its Form 10-K filed with the U.S. Securities and Exchange Commission on 26 February 2026. The forthcoming Hong Kong release will replicate those figures and include the additional disclosures and the U.S. GAAP-to-IFRS reconciliation mandated by the Hong Kong Listing Rules.

Board composition remains unchanged, with Mr. John V. Oyler serving as Chairman and Executive Director, supported by one Non-executive Director and nine Independent Non-executive Directors.

The announcement clarifies that the Hong Kong publication will comply fully with local listing requirements while maintaining consistency with the previously filed U.S. financial statements.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1103614453?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-11 18:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1103614453","market":"us","top_or_hot":-1,"title":"BEIGENE (06160) Schedules 25 Mar 2026 Audit Committee Meeting to Confirm FY2025 Results and HKEX Disclosure","media":"Bulletin Express","content":"<p>BeOne Medicines Ltd. (trading as BEIGENE; stock code 06160) has announced that its Board Audit Committee will convene on 25 March 2026 (Hong Kong time) to review and approve the consolidated annual results for the financial year ended 31 December 2025.</p>\n<p>The company previously disclosed the same FY2025 financials in its Form 10-K filed with the U.S. Securities and Exchange Commission on 26 February 2026. The forthcoming Hong Kong release will replicate those figures and include the additional disclosures and the U.S. GAAP-to-IFRS reconciliation mandated by the Hong Kong Listing Rules.</p>\n<p>Board composition remains unchanged, with Mr. John V. Oyler serving as Chairman and Executive Director, supported by one Non-executive Director and nine Independent Non-executive Directors.</p>\n<p>The announcement clarifies that the Hong Kong publication will comply fully with local listing requirements while maintaining consistency with the previously filed U.S. financial statements.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BEIGENE (06160) Schedules 25 Mar 2026 Audit Committee Meeting to Confirm FY2025 Results and HKEX Disclosure</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBEIGENE (06160) Schedules 25 Mar 2026 Audit Committee Meeting to Confirm FY2025 Results and HKEX Disclosure\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-11 18:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BeOne Medicines Ltd. (trading as BEIGENE; stock code 06160) has announced that its Board Audit Committee will convene on 25 March 2026 (Hong Kong time) to review and approve the consolidated annual results for the financial year ended 31 December 2025.</p>\n<p>The company previously disclosed the same FY2025 financials in its Form 10-K filed with the U.S. Securities and Exchange Commission on 26 February 2026. The forthcoming Hong Kong release will replicate those figures and include the additional disclosures and the U.S. GAAP-to-IFRS reconciliation mandated by the Hong Kong Listing Rules.</p>\n<p>Board composition remains unchanged, with Mr. John V. Oyler serving as Chairman and Executive Director, supported by one Non-executive Director and nine Independent Non-executive Directors.</p>\n<p>The announcement clarifies that the Hong Kong publication will comply fully with local listing requirements while maintaining consistency with the previously filed U.S. financial statements.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06160","symbol_name":"百济神州","start_time":0,"source_url":"","article_id":"1103614453","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1103614453","pubTimestamp":1773223404,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"BeOne Medicines Ltd. (trading as BEIGENE; stock code 06160) has announced that its Board Audit Committee will convene on 25 March 2026 (Hong Kong time) to review and approve the consolidated annual...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06160":"百济神州"},"translate_title":"百济神州(06160)安排2026年3月25日审核委员会会议确认2025财年业绩及港交所披露","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06160":1},"content_text":"BeOne Medicines Ltd. (trading as BEIGENE; stock code 06160) has announced that its Board Audit Committee will convene on 25 March 2026 (Hong Kong time) to review and approve the consolidated annual results for the financial year ended 31 December 2025.\nThe company previously disclosed the same FY2025 financials in its Form 10-K filed with the U.S. Securities and Exchange Commission on 26 February 2026. The forthcoming Hong Kong release will replicate those figures and include the additional disclosures and the U.S. GAAP-to-IFRS reconciliation mandated by the Hong Kong Listing Rules.\nBoard composition remains unchanged, with Mr. John V. Oyler serving as Chairman and Executive Director, supported by one Non-executive Director and nine Independent Non-executive Directors.\nThe announcement clarifies that the Hong Kong publication will comply fully with local listing requirements while maintaining consistency with the previously filed U.S. financial statements.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1103614453","isCrawlerRequest":true}